This week Pfizer, along with its German partner company BioNTech, announced that its Covid-19 vaccine is more than 90% effective at preventing infection. The announcement generated excitement throughout the world, sent the stock market soaring and also raised questions about how the vaccine would be priced and distributed if it is approved by the Food and Drug Administration.
Pfizer has stated that their vaccine will be made available at no cost, and the corporation has agreed to supply 100 million doses to the United States at a price of $39 for a two-shot course, or $19.50 per dose. Pfizer’s touting a “free” vaccine rings hollow, since the pharmaceutical corporation has benefitted from millions in tax breaks over the last two years and will receive significant support from the federal government to distribute the vaccine across the country.
“Progress toward an effective vaccine gives us some hope for containing the virus and preventing unneeded death. However, we must continue to fight to ensure any coronavirus vaccine or treatment is free and available to all who need it, no matter where they live,” said Joseph Peters, Jr., Secretary-Treasurer of the Alliance.
The Make Medications Affordable by Preventing Pandemic Price-gouging (MMAPPP) Act, introduced by Representatives Jan Schakowsky (IL), Francis Rooney (FL), Lloyd Doggett (TX), Rosa DeLauro (CT), and Peter DeFazio (OR), would ensure that any taxpayer-funded vaccines or treatments for COVID-19 proven to be safe and effective will be accessible, affordable, and available to all who need them.